Trial
NCT00537316
Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Infliximab (IFX)
Why stopped
Infusion reactions during re-induction cycles after a period of no treatment in another study \[P04563, NCT0358670\]
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-12